1. Replication of Genetic Markers Associated with Clozapine-Induced Agranulocytosis
- Author
-
Michael Lachowicz, Maria Athanasiou, Anil K. Malhotra, Igor Mosyagin, John M. Kane, Stanton L. Gerson, Ingolf Cascorbi, Michael Dettling, Carol R. Reed, and Brad Dain
- Subjects
Candidate gene ,HLA-DQB1 ,Side effect ,business.industry ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Bioinformatics ,Biochemistry ,Monitoring program ,Schizophrenia ,Cohort ,Medicine ,business ,Adverse effect ,Clozapine ,medicine.drug - Abstract
Clozapine is a highly efficacious drug for the treatment of schizophrenia, but its use is limited, in part due to the side effect of agranulocytosis. In order to reduce the incidence of clozapine-induced agranulocytosis (CIA), patients are required to submit to a blood monitoring program. A genetic component to CIA is suggested by published associations in a number of genes. A genetic test assessing the risk of CIA might allow safer and more broad use of clozapine. We previously conducted a candidate gene-based case-control study to discover genes associated with CIA. Cases were patients with an ANC A replication analysis was performed on an independently collected cohort of 49 cases and 78 controls from Germany. Cases were patients who developed an ANC
- Published
- 2006